GlobeNewsWire · 2 Oct 2026neutral
Damora Therapeutics announced that it granted equity inducement awards to five newly-hired, non-executive employees on October 1, 2026. The grants were approved by the independent Compensation Committee and made in accordance with Nasdaq Listing Rule 5635(c)(4) to serve as material inducements for accepting employment.
Why it matters — A DMRA watcher would care because this reflects the company's hiring and equity-compensation activity for new employees, which could indicate organizational growth in its blood-disorder work.
GlobeNewsWire · 3 Sept 2026neutral
Damora Therapeutics announced that on September 1, 2026, it granted equity awards to three newly-hired, non-executive employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were part of inducement grants to attract new talent.
Why it matters — DMRA watchers would care because these inducement grants signal new hires joining the company, which may indicate ongoing workforce growth as it pursues its work in blood disorders.
Seeking Alpha · 12 Aug 2026positive
Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, offers superior potency and half-life over comparators, with proof-of-concept data expected mid-2027 and a potential Phase 3 start in mid-2028.
Why it matters — A Damora Therapeutics watcher would care because the article highlights competitive validation of its target and positions the company's pipeline and lead candidate's advantages as the basis for future upside potential.
GlobeNewsWire · 5 Aug 2026positive
Damora Therapeutics announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational antibody therapy targeting mutant calreticulin, in patients with mutCALR-driven essential thrombocythemia and myelofibrosis, following health authority approval. The company noted that DMR-001 is designed for once-monthly subcutaneous dosing and that preclinical studies showed it had greater potency and a longer half-life than a reference anti-mutCALR antibody.
Why it matters — This marks the start of clinical testing for DMR-001, a lead pipeline candidate for Damora, and provides the first clinical data readouts that could validate its preclinical profile in a defined patient population.
GlobeNewsWire · 3 Aug 2026neutral
Damora Therapeutics announced that on August 1, 2026, it granted equity awards to six newly-hired, non-executive employees. The inducement grants were approved by the independent Compensation Committee and made as material inducements to employment acceptance under Nasdaq Listing Rule 5635(c)(4).
Why it matters — A DMRA watcher would care because this shows the company is hiring and incentivizing new employees through equity, a routine governance disclosure with no direct impact on its commercial or clinical outlook.
